Description
Afatinib tablets are targeted anticancer agents used to treat non-small cell lung cancer (NSCLC) with specific EGFR mutations. By irreversibly inhibiting EGFR and related pathways, they slow tumor growth, enhance survival, and offer a precision-based approach to advanced lung cancer management.